Teva Pharmaceutical Industries (TEVA) Getting Somewhat Favorable Press Coverage, Accern Reports

News articles about Teva Pharmaceutical Industries (NYSE:TEVA) have been trending somewhat positive this week, Accern Sentiment reports. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Teva Pharmaceutical Industries earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned news articles about the company an impact score of 44.559662355862 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Here are some of the news articles that may have effected Accern Sentiment’s analysis:

How to Become a New Pot Stock Millionaire

Teva Pharmaceutical Industries (TEVA) traded down $0.23 during trading on Tuesday, hitting $17.68. 14,399,867 shares of the stock were exchanged, compared to its average volume of 17,223,588. The stock has a market cap of $18,680.03, a P/E ratio of -1.09, a price-to-earnings-growth ratio of 1.60 and a beta of 0.65. Teva Pharmaceutical Industries has a twelve month low of $10.85 and a twelve month high of $33.82. The company has a quick ratio of 0.58, a current ratio of 0.86 and a debt-to-equity ratio of 1.91.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Thursday, February 8th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.14. The business had revenue of $5.46 billion for the quarter, compared to the consensus estimate of $5.29 billion. Teva Pharmaceutical Industries had a negative net margin of 72.66% and a positive return on equity of 16.43%. The business’s revenue was down 15.9% on a year-over-year basis. During the same period in the previous year, the firm earned $1.38 EPS. equities research analysts forecast that Teva Pharmaceutical Industries will post 2.3 earnings per share for the current year.

A number of equities analysts have commented on TEVA shares. BTIG Research lifted their target price on shares of Teva Pharmaceutical Industries to $20.00 in a research note on Friday, December 15th. Goldman Sachs raised shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and set a $20.00 target price on the stock in a research note on Friday, December 15th. ValuEngine raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Tuesday, December 5th. Citigroup raised shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and set a $24.00 target price on the stock in a research note on Thursday, January 4th. Finally, Mizuho raised shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $19.12 to $23.00 in a research note on Tuesday, January 9th. Ten equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and eight have assigned a buy rating to the company’s stock. Teva Pharmaceutical Industries currently has an average rating of “Hold” and an average price target of $20.83.

In other news, EVP Mark Sabag sold 5,050 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $19.68, for a total value of $99,384.00. Following the sale, the executive vice president now directly owns 44,517 shares of the company’s stock, valued at approximately $876,094.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 10,734 shares of company stock worth $204,795 over the last three months. Insiders own 7.10% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Stock Observer and is owned by of Stock Observer. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.thestockobserver.com/2018/03/20/teva-pharmaceutical-industries-teva-getting-somewhat-favorable-press-coverage-accern-reports.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Insider Buying and Selling by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply